Can you take Thymoglobulin with Ublituximab?

The anti-thymocyte globulin (rabbit) in Thymoglobulin has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression. To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use. Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments. It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated. Also, total white blood cell and platelet counts should be monitored.

The anti-thymocyte globulin (rabbit) in Thymoglobulin has a major potential interaction with Immunodeficiency.

The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression. To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use. Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments. It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated. Also, total white blood cell and platelet counts should be monitored.

Ublituximab has a moderate potential interaction with Immunodeficiency.

Ublituximab has been associated with serious, including life-threatening or fatal, bacterial and viral infections. Delay treatment in patients with active infection until resolution. Monitor the levels of quantitative serum immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections, and after discontinuation of therapy until B-cell repletion. For patients with low serum immunoglobulins, consult immunology experts before initiating therapy. Consider treatment discontinuation if a patient with low immunoglobulins develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires therapy with IV immunoglobulins.

The anti-thymocyte globulin (rabbit) in Thymoglobulin has a major potential interaction with Infection.

The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression. To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use. Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments. It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated. Also, total white blood cell and platelet counts should be monitored.

Ublituximab has a moderate potential interaction with Infection.

Ublituximab has been associated with serious, including life-threatening or fatal, bacterial and viral infections. Delay treatment in patients with active infection until resolution. Monitor the levels of quantitative serum immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections, and after discontinuation of therapy until B-cell repletion. For patients with low serum immunoglobulins, consult immunology experts before initiating therapy. Consider treatment discontinuation if a patient with low immunoglobulins develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires therapy with IV immunoglobulins.

Ublituximab has a major potential interaction with Infectious Hepatitis.

Use of ublituximab is contraindicated in patients with active hepatitis b virus (HBV) infection. Reactivation of HBV has been reported with use of ublituximab. Perform HBV screening in all patients prior to therapy. Consult a liver disease expert in patients who are negative for surface antigen (HBsAg) and positive for HB core antibody (HBcAb+), or are carriers of HBV (HBcAb+).

Ublituximab has a moderate potential interaction with Liver Disease.

Ublituximab may cause liver injury. Patients with ALT/AST greater than 3 times the upper limit of normal (3 x ULN) and total bilirubin greater than 2 x ULN are at risk for severe drug-induced liver injury. The effect of moderate to severe liver dysfunction on the pharmacokinetics of ublituximab is unknown. Prior to therapy with ublituximab, assess ALT, AST, alkaline phosphatase, and bilirubin levels. Monitor for signs and symptoms of any drug-induced liver injury during treatment; discontinue therapy if identified.

Ublituximab has a moderate potential interaction with Renal Dysfunction.

The effect of moderate to severe renal dysfunction on the pharmacokinetics of ublituximab is unknown.

The anti-thymocyte globulin (rabbit) in Thymoglobulin has a major potential interaction with Vaccination.

Patients recently treated with anti-thymocyte globulin [rabbit] should not receive immunizations with live viral vaccines.